Interleukin-2 (IL2)

A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes.

Also Known As:

IL2; Interleukin 2; IL-2; Interleukin II; Interleukine 2; RU 49637; RU-49637; Ro-23-6019; Ro-236019; T-Cell Stimulating Factor; Thymocyte Stimulating Factor; Mitogenic Factor, Lymphocyte; RU49637; Ro 23 6019; Ro 236019; Ro236019; T Cell Growth Factor; T Cell Stimulating Factor; Lymphocyte Mitogenic Factor; T-Cell Growth Factor; TCGF

Networked: 17447 relevant articles (1264 outcomes, 2476 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Rosenberg, Steven A: 58 articles (10/2021 - 01/2002)
2.	Atkins, Michael B: 39 articles (07/2015 - 06/2002)
3.	Tsokos, George C: 37 articles (01/2022 - 05/2002)
4.	Neri, Dario: 34 articles (01/2021 - 03/2002)
5.	Sondel, Paul M: 30 articles (12/2022 - 01/2004)
6.	Kaufman, Howard L: 30 articles (12/2021 - 03/2002)
7.	McDermott, David F: 30 articles (01/2019 - 10/2002)
8.	Restifo, Nicholas P: 26 articles (05/2017 - 08/2003)
9.	Klatzmann, David: 23 articles (01/2022 - 06/2003)
10.	Hwu, Patrick: 23 articles (01/2020 - 05/2002)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2022 - "MDNA11 is a next generation long-acting IL-2 immunotherapeutic with a highly favorable pharmacodynamic profile that translates to a strong therapeutic efficacy in preclinical tumor models and a strong and durable immune response in NHP." 01/01/1993 - "On the other hand, several groups have shown that application of intratumoral low doses of IL-2 can be highly effective against cancer and without toxic side-effects. " 04/01/1991 - "Fewer pulmonary tumor colonies were observed in those animals treated with IL-2, and the best results were observed when IL-2 was administered prior to tumor inoculation. " 09/15/1985 - "While marked success has been demonstrated over the years in tumor-bearing animal models, the feasibility of such work in humans has been greatly improved by the experimental expansion and maintenance of immune lymphocytes (those exposed to antigenic challenge) in vitro using either highly purified or recombinant, interleukin 2. As a result, large numbers of lymphocytes can successfully be infused into patients, and whole body scans can show migration of these labeled cells to the lung, liver, and spleen. " 03/01/1994 - "First noted in murine studies, the antitumor efficacy of IL-2 has been shown to induce partial and complete regression of some tumors in human clinical trials over the past decade. "
2.	Melanoma (Melanoma, Malignant) 04/01/2006 - "A variety of immunotherapeutic approaches have shown activity in patients with metastatic melanoma with the best results being observed with interleukin 2 (IL-2). " 08/01/2003 - "Adjuvant treatment of intermediate- and high-risk melanoma patients with low-dose IFNalpha2b and IL-2 is safe and well tolerated by most patients, but it does not improve disease-free or overall survival." 12/01/2017 - "Expert opinion: High-dose IL-2 remains an important option for patients with melanoma and has an improved therapeutic window in the contemporary era. " 01/01/2019 - "The objective of this study was to evaluate the feasibility, safety, and efficacy of combination high-dose IPI and high-dose IL-2 in patients with histologically confirmed advanced unresectable stage III and IV melanoma. " 01/01/2013 - "This study assessed the safety and therapeutic efficacy of high-dose IL-2 in patients ≥65 years of age with metastatic melanoma and RCC. "
3.	Neoplasm Metastasis (Metastasis) 01/01/2019 - "POM-1 was highly effective in suppressing metastases when used in combination with BRAFi/MEKi or anti-PD-1/anti-CTLA-4 or IL-2. " 01/01/1995 - "Of 33 patients, one achieved a complete remission (response duration, 24 months) and two patients presented with partial remissions (median response duration, 7 months) of pulmonary metastases upon rIFN-alpha/5-FU after failing SC recombinant interleukin-2 (rIL-2) and rIFN-alpha. " 12/01/1986 - "A single patient with pulmonary and hepatic metastases showed marked decrease in these lesions with intraperitoneal IL-2 treatment. " 04/01/2004 - "Inhalation of IL-2 for the treatment of pulmonary metastases in RCC is feasible, tolerable and beneficial in controlling progressive disease for considerable periods of time. " 09/01/1989 - "In one experiment with 10-d pulmonary metastases, increased administration of IL-2 made possible by passive immunization against TNF significantly improved the antitumor response compared to equitoxic doses of IL-2 and control antibody. "
4.	Renal Cell Carcinoma (Grawitz Tumor) 02/01/2000 - "With prolonged follow-up, treatment with high-dose recombinant IL-2 remains extremely effective for a subset of patients with metastatic renal cell carcinoma." 09/01/2011 - "Although the new agents result in a progression-free survival benefit, high-dose IL-2 remains the only agent with proven efficacy in producing durable complete and partial responses in patients with metastatic renal cell carcinoma (RCC). " 11/01/2005 - "Interleukin-2 (IL-2) has been shown to produce durable complete remission in patients with renal cell carcinoma (RCC). " 01/17/1990 - "A phase II trial of intermittent high-dose recombinant interleukin-2 (rIL-2) was initiated to evaluate the response rate, remission duration, and toxic effects in patients with measurable metastatic renal cell carcinoma. " 06/01/1987 - "IL-2 induced significantly greater cytotoxicity against renal carcinoma cells than did IFN-gamma. "
5.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 06/30/2011 - "IL-2 monotherapy has been evaluated in several randomized clinical trials (RCTs) for remission maintenance in patients with acute myeloid leukemia (AML) in first complete remission (CR1), and none demonstrated a significant benefit of IL-2 monotherapy. " 04/01/1999 - "The authors investigated whether IL-2 may improve the duration of complete remission (CR) and survival in acute myelogenous leukemia (AML) patients in first CR. " 04/01/1999 - "A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission." 07/01/1996 - "Achievement and maintenance of complete remission in a patient with acute myelogenous leukemia after weekly administration of interleukin-2." 02/01/2000 - "The dose and schedule of IL-2 used in these two trials continue to be reasonably well tolerated by children with acute myelogenous leukemia in first remission. "

Related Drugs and Biologics

1.	Cytokines
2.	Interleukin-2 (IL2)
3.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
4.	Vaccines
5.	Interleukin-4 (Interleukin 4)
6.	Interferon-alpha (Interferon Alfa)
7.	Interleukin-12 (IL 12)
8.	Interferons
9.	Interleukin-6 (Interleukin 6)
10.	Interferon-gamma (Interferon, gamma)

Related Therapies and Procedures

1.	Therapeutics
2.	Immunotherapy
3.	Drug Therapy (Chemotherapy)
4.	Injections
5.	Transplantation